CEO Frank Bedu-Addo highlighted the initiation of the VERSATILE 003 Phase 3 clinical trial of Versamune HPV plus pembrolizumab for first-line recurrence and/or metastatic HPV16-positive head and neck ...

Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Enrollment ongoing in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC ...

The maker of an at-home cervical cancer screening test said Friday it has won approval from the Food and Drug Administration, ...

Conclusions: Lorlatinib demonstrates strong efficacy and manageable safety, especially in first-line treatment of advanced ALK-positive NSCLC ... NSCLC patients were adenocarcinoma (n=61), squamous ...

Abpro Holdings, Inc. and Celltrion have announced a strategic partnership for the global development of ABP-102/CT-P72, a bispecific T-cell engager designed to target HER2-positive cancers ...

but it can prevent the most HPV-positive oropharyngeal cancer cases. In terms of vaccination effectiveness, the bivalent HPV vaccine prevented 1,479,990 cases of high-risk HPV persistent infections, ...

More information: Ying Chen et al, A systematic benchmark of Nanopore long-read RNA sequencing for transcript-level analysis in human cell lines, Nature Methods (2025). DOI: 10.1038/s41592-025-02623-4 ...

The incidence of HPV-associated (HPV+) head and neck squamous cell carcinoma (HNSCC ... Aurora kinase A inhibition overcomes tolerance to panHER inhibitors in HPV positive HNSCC [abstract]. In: ...

Although HER2-targeted ADCs have shown marked efficacy for HER2 mutation-positive NSCLC ... the HER2 internalization in cells stably expressing WT forms of HER2, such internalization was not affected ...

EcDNA is made up of small, circular segments of DNA that form outside of chromosomes within the cell ... integration of HPV genes and human DNA is present in about 30% of HPV-positive ...